// App-Quantinova.ai

2001 : EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma.

Researchers

Presenter

  • Wolfgang Wick

Principal Investigators

  • Thierry Gorlia

  • Martin Bendszus

  • Felix Sahm

  • Walter Taal

  • Martin J.B. Taphoorn

  • Julien Domont

  • Ahmed Idbaih

  • Mario Campone

  • Paul M. Clement

  • Roger Stupp

  • Michel Fabbro

  • Emilie Le Rhun

  • Francois Dubois

  • Martin Klein

  • Michael Platten

  • Michael Weller

  • Vassilis Golfinopoulos

  • Martin J. Van Den Bent

Medical Centers

  • University of Heidelberg Medical Center, Heidelberg, Germany

  • Azienda USL Bellaria-Maggiore Hospital, Bologna, Italy

  • European Organisation for Research and Treatment of Cancer, Bruxels, Belgium

  • Heidelberg University Hospital, Heidelberg, Germany

  • Heidelberg University Hospital, German Cancer Research Center (DKFZ), Heidelberg, Germany

  • Erasmus MC, Rotterdam, Netherlands

  • Medisch Centrum Haaglanden, The Hague, Netherlands

  • Institut Gustave-Roussy, Villejuif, France

  • Universite Pierre et Marie Curie Paris VI, Paris, France

  • Cancer Institute of the West (ICO), Centre Rene Gauducheau, Medical Oncology Department, Saint-Herblain, France

  • UZ Leuven-Gasthuisberg, Leuven, Belgium

  • University of Lausanne Hospitals, Lausanne, Switzerland

  • CRLC Val d'Aurelle, Montpellier, France

  • Centre Oscar Lambret, Lille, France

  • CHRU, Lille, France

  • VU Amsterdam, Amsterdam, Netherlands

  • Heidelberg University Hospital, German Cancer Research Center (DKFZ), Heidelberg, Germany

  • European Organisation for Research and Treatment of Cancer, Bruxels, Belgium

  • Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, Netherlands

Locations

  • Italy

  • Netherlands

  • Germany

  • Switzerland

  • France

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • N/A

Drug/Treatment

  • Bevacizumab

  • Lomustine

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01290939

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved